Common Dosage
250mcg - 500mcg twice daily
Category
Recovery
- Accelerated wound healing
- Anti-inflammatory
- Tendon and ligament repair
- Gut health improvement
BPC-157 (Body Protection Compound-157) is a pentadecapeptide first isolated from human gastric juice in the 1990s by Dr. Predrag Sikiric and colleagues at the University of Zagreb. The research team was investigating compounds naturally present in the stomach that might protect the gastrointestinal lining. They identified a 15-amino-acid sequence — BPC-157 — as particularly potent in its protective and regenerative effects. Over the following three decades, Sikiric's group published hundreds of papers examining its effects across virtually every organ system, making it one of the most thoroughly studied research peptides in the peptide community.
BPC-157 works through several parallel pathways. It significantly upregulates growth hormone receptors, modulates the nitric oxide (NO) system to improve blood flow and vascular repair, and activates the FAK-paxillin pathway involved in cell migration and wound closure. It also interacts with the dopamine and serotonin systems, which explains some of its systemic stabilizing effects. Unlike many peptides, BPC-157 appears to be a true pleiotropic agent — it achieves healing through multiple mechanisms simultaneously rather than a single target.
- Tendon and ligament injury repair — among the best-studied applications, with multiple rodent models showing accelerated collagen deposition and structural recovery
- Gut and gastrointestinal healing — including IBD, leaky gut, NSAID-induced damage, and fistula repair
- Muscle tear and crush injury recovery
- Bone fracture healing acceleration
- Neuroprotection and TBI recovery in animal models
- Corneal injury and wound healing
- Periodontitis and dental tissue repair
- Liver and organ protection from toxic insult
Achilles Tendon Recovery
A well-known case series in the research community involves athletes with chronic Achilles tendinopathy who reported significant pain reduction and return-to-sport within 4–6 weeks of twice-daily subcutaneous BPC-157 at 500mcg. MRI follow-up in some cases suggested improved tendon signal intensity consistent with tissue remodeling.
Post-Surgical Gut Recovery
Several anecdotal clinical reports from integrative practitioners describe faster return of bowel function and reduced anastomotic leak rates when BPC-157 was added to post-surgical protocols. The mechanism aligns with its documented effect on intestinal epithelial cell migration and blood vessel formation.
Crohn's Disease Adjunct
Practitioners using BPC-157 alongside standard Crohn's therapy have reported subjective reductions in flare frequency and stool irregularity. Animal studies in colitis models show measurable mucosal repair and reduced pro-inflammatory cytokine expression, providing mechanistic support.
- No completed human clinical trials as of 2025 — all efficacy data extrapolated from animal studies and anecdotal reports
- Potential interaction with the dopamine/serotonin system warrants caution for individuals on psychiatric medications
- Source purity is critical — the research peptide market has variable quality controls, and contaminated batches carry real risk
- Long-term effects on growth factor signaling are unknown; theoretical concern exists regarding cellular proliferation in pre-cancerous tissue
- Not FDA-approved; regulatory status varies internationally
- Nausea (rare)
- Headache (rare)